Keywords COVID-19 vaccine multiple myeloma SARS-CoV-2 hematology oncology COVID-19 mRNA vaccines are highly efficacious in preventing COVID-19 morbidity and mortality in phase 3 clinical studies as well as in real-world settings. Emerging evidence suggests that some individuals with underlying comorbidities may mount suboptimal antibody responses to SARS-CoV-2 immunization (; Monin et al., 2021 Monin L. Laing A.G. Muñoz-Ruiz M. McKenzie D.R. Del Molino Del Barrio I. Alaguthurai T. Domingo-Vila C.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Sarita
Contact Sarita, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack